Drug news
The Medicines Company files cangrelor at FDA to treat PCI
The FDA has accepted the new drug application (NDA) for The Medicines Company intravenous antiplatelet cangrelor as a treatment in patients undergoing Percutaneous Coronary Intervention (PCI) and those that require bridging from oral antiplatelet therapy to surgery.
If the review is successful the company anticipates a US market approval in the second quarter of 2014, and hopes for a European submission in the fourth quarter 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins